THE CHOICE OF CHEMOTHERAPEUTIC TREATMENT OF BREAST CANCER (TAKING INTO ACCOUNT THE BIOLOGICAL SUBTYPES IN OLDER WOMEN)
Alimkhodzhaeva L.T.*, Yusupova N.B, Shodmonova D.S., Abdullaeva G.D. and Narzieva D.F.
Patients with the hormone-sensitive and Her2neu amplified tumor subtype have a better short-term prognosis than patients with the hormone-negative and Erb-B2 overexpressing subtype. With triple-negative breast cancer, chemotherapy is the only systemic therapy that is beneficial, and should be used in patients who are in good physical shape.
Keywords: breast cancer, targeted and systemic chemotherapy, luminal A subtype, luminal B subtype, HER2 protein.
[Full Text Article]